A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus

Autoimmunity Reviews

Volumn 10, Issue 1, 2010, Pages 22-26

  Mozes, Edna ^a   Sharabi, Amir ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

A tolerogenic peptide; Apoptosis; CD4 and CD8 regulatory T cells; Cytokines; Systemic lupus erythematosus

Indexed keywords

B CELL ACTIVATING FACTOR; GAMMA INTERFERON; HCDR1; INTERLEUKIN 10; INTERLEUKIN 1BETA; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SWINE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; AUTOANTIGENS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; NERVE TISSUE PROTEINS; PEPTIDES; SWINE;

EID: 78149358811     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.004     Document Type: Review

References (40)

1. Hahn B.H. Overview of pathogenesis of systemic lupus erythematosus. Dubious' lupus erythematosus 2006, 46-53. Lippincott Williams & Wilkins, Philadelphia. D.J. Wallace, B.H. Hahn (Eds.).
2. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythemathosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003, 131:385-392.
3. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 1995, 7:689-696.
4. Luger D., Dayan M., Zinger H., Liu J.-P., Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004, 24:579-590.
5. Blank M., Shoenfeld Y. The story of 16/6 idiotype and systemic lupus erythematosus. Isr Med Assoc J 2008, 10:37-39.
6. Mauermann N., Sthoeger Z., Zinger H., Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004, 137:513-520.
7. Lapter S., Marom A., Meshorer A., Elman A., Sharabi A., Vadai E., et al. Amelioration of brain pathology and behavioral dysfunction of mice with systemic lupus erythematosus following treatment with a tolerogenic peptide. Arthritis Rheum 2009, 60:3744-3754.
8. Horowitz D.A., Jacob C.O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994, 16:181-200.
9. Dean G.S., Tyrrel-Price J., Crawley E., Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000, 59:243-251.
10. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZBxNZW)F1 mice. J Immunol 1998, 160:3713-3718.
11. Baccala R., Kono D.H., Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005, 204:9-26.
12. Sharabi A., Sthoeger Z.M., Mahlab K., Lapter S., Zinger H., Mozes E. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-γ signaling in lupus-affected (NZBxNZW)F1 mice. Clin Immunol 2009, 133:61-68.
13. Karonitch E., Feirl E., Steiner C.W., Dalwigk K., Korb A., Binder N. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 2009, 60:1463-1471.
14. Sakaguchi S., Yamaguchi T., Nomuta T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
15. Kang H.K., Michaels M.A., Berner B.R., Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005, 174:3247-3255.
16. Gerli R., Nocentini G., Alunno A., Bartoloni Boci E., Bianchini R., Bistoni O., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009, 8:426-430.
17. + Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 2010, 9:560-568.
18. + T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001, 166:6452-6457.
19. + cells and TGF-β Proc Natl Acad Sci USA 2006, 103:8810-8815.
20. Mozes E., Sela U., Sharabi A. A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action. Isr Med Assoc J 2008, 10:40-42.
21. Sharabi A., Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol 2008, 181:3243-3251.
22. - cells in mice. PLoS ONE 2009, 4:e8447.
23. Navratil J.S., Ahearn J.M. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep 2001, 3:191-198.
24. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007, 179:4979-4987.
25. Sharabi A., Haviv A., Zinger H., Dayan M., Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared with dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 2006, 119:146-155.
26. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 2005, 117:262-270.
27. Rincon M., Enslen H., Raingeaud J., Recht M., Zapton T., Su M.S., et al. Interferon-γ expression by Th1 effector T cells mediated by p38 MAP kinase signaling pathway. EMBO J 1998, 17:2817-2829.
28. Green D.R., Droin N., Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003, 193:70-81.
29. Sharabi A., Azulai H., Sthoeger Z.M., Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: Similarities and differences in the mechanisms of action. Immunology 2007, 121:248-257.
30. Sharabi A., Lapter S., Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun 2010, 34:87-95.
31. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006, 5:564-576.
32. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
33. Mackay F., Sierro F., Grey S.T., Gordon T.P. The BAFF/April system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265.
34. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
35. Cheema G.S., Roscke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatoid diseases. Arthritis Rheum 2001, 44:1313-1319.
36. Parameswarran R., Ben David H., Sharabi A., Zinger H., Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol 2009, 131:223-232.
37. Enzler T., Bonizzi G., Silverman G.L., Otero D.C., Widhopf G.F., Anzelon-Mills A., et al. Alternative and classical NF-kB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
38. Sharabi A., Dayan M., Zinger H., Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol 2010, 30:34-44.
39. Sthoeger Z.M., Sharabi A., Dayan M., Zinger H., Asher I., Sela U., et al. The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol 2009, 70:139-145.
40. Sthoeger Z.M., Sharabi A., Molad Y., Asher I., Zinger H., Dayan M., et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009, 33:77-82.